In this special edition of EP Edge® Journal Watch, Dr. Sharma reviews the major breaking cardiovascular and electrophysiology science presented at the European Society of Cardiology Congress 2026 in Munich. The episode begins with two important electrophysiology trials that challenge familiar clinical thresholds. First is SINGLE-AF, led by Daehoon Kim and colleagues and published in the New England Journal of Medicine in August 2026. The trial provides the first randomized evidence evaluating direct oral anticoagulation versus no anticoagulation in patients with atrial fibrillation at intermediate stroke risk. Dr. Sharma explains why this population has remained a clinical gray zone, how the trial was designed, what the 69% relative reduction in the primary net clinical endpoint actually means, why the absolute event rate remains important, and whether these findings should change anticoagulation decisions in everyday AF practice. Next is CMR GUIDE, led by Joseph B. Selvanayagam and colleagues and published in JAMA in August 2026. This provocative randomized trial tested whether myocardial scar identified by late gadolinium enhancement cardiac MRI could help identify patients with LVEF 36% to 50% who may benefit from a primary-prevention ICD. Although the primary endpoint was neutral, the reduction in sudden cardiac death and the striking signal among patients younger than 70 years raise a much larger question for electrophysiologists: Is LVEF alone still an adequate way to determine sudden cardiac death risk and ICD candidacy? The episode then moves into a rapid review of additional major developments from ESC 2026. The 2026 ESC Heart Failure Guidelines, led by Lars Køber, Marianna Adamo and colleagues and published in the European Heart Journal, eliminate the traditional HFmrEF category, redefine HFrEF as LVEF below 50%, introduce a Stage A through D heart failure framework, and reorganize therapy into foundational, additional, and guideline-directed interventional treatment. Dr. Sharma discusses why this major change in heart failure classification does not automatically change ICD or CRT indications, but may influence how future device therapy is studied. The Fifth Universal Definition of Myocardial Infarction, led by Nicholas Mills, L. Kristin Newby, Sarah Zaman and colleagues, introduces a simpler pathophysiologic classification of primary MI, secondary MI, and procedure-related MI. Of particular relevance to electrophysiology, the new framework may help clarify how elevated troponin should be interpreted in patients with rapid atrial fibrillation and other tachyarrhythmias, separating true ischemic myocardial infarction from acute myocardial injury. Also discussed is the major Nature Reviews Cardiology review led by Thomas Münzel and colleagues examining nicotine and cardiovascular disease. The review places combustible cigarettes, heated tobacco products, e-cigarettes, and oral nicotine products along a continuum of cardiovascular harm and emphasizes that reduced exposure to combustion does not make nicotine-containing products cardiovascularly neutral. Finally, Dr. Sharma examines an innovative study presented by Viana Copeland and colleagues using artificial intelligence to analyze nearly 100,000 mammograms for cardiovascular signals associated with hypertension, ischemic heart disease, and stroke. The concept raises the intriguing possibility that imaging obtained for one clinical purpose may ultimately provide useful information about entirely different disease phenotypes. Throughout the episode, the emphasis is not simply on reporting trial results. Dr. Sharma explains why each study was needed, how it was designed, what the statistics actually mean, what the limitations are, and how the findings may influence clinical electrophysiology practice. Topics include: ESC Congress 2026 Munich SINGLE-AF trial atrial fibrillation and anticoagulation CHA₂DS₂-VA and intermediate stroke risk DOAC therapy CMR GUIDE trial cardiac MRI and late gadolinium enhancement myocardial scar and sudden cardiac death primary-prevention ICD therapy LVEF greater than 35% 2026 ESC Heart Failure Guidelines HFrEF and HFpEF Fifth Universal Definition of Myocardial Infarction Type 2 MI and tachyarrhythmias nicotine and cardiovascular disease vaping and cardiovascular risk artificial intelligence in cardiovascular imaging AI mammography and cardiovascular screening cardiac electrophysiology sudden cardiac death risk stratification For the full statistical analysis, references, figures, and graphics, read EP Edge® Journal Watch on LinkedIn and Substack at epedge.substack.com. Questions, suggestions, or concerns: epedge.cast@gmail.com.
